FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors

By L. Marcus, L. Fashoyin-Aje, Martha Donoghue, Mengdie Yuan, Lisa R Rodriguez, Pamela S. Gallagher, Reena Philip, Soma Ghosh, M. Theoret, J. Beaver and 2 more. 2021

Subfields: Cancer Research, Oncology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Similarly, tumor mutational burden (TMB) was included as a companion biomarker in the United States’ Food and Drug Administration (FDA) approval, where patients with TMB ≥ 10 mutations/megabase can qualify for Pembrolizumab treatment [10].”